W. Lau

1.2k total citations
9 papers, 893 citations indexed

About

W. Lau is a scholar working on Infectious Diseases, Epidemiology and Small Animals. According to data from OpenAlex, W. Lau has authored 9 papers receiving a total of 893 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 8 papers in Epidemiology and 5 papers in Small Animals. Recurrent topics in W. Lau's work include Antifungal resistance and susceptibility (8 papers), Fungal Infections and Studies (6 papers) and Infectious Diseases and Mycology (5 papers). W. Lau is often cited by papers focused on Antifungal resistance and susceptibility (8 papers), Fungal Infections and Studies (6 papers) and Infectious Diseases and Mycology (5 papers). W. Lau collaborates with scholars based in United States, United Kingdom and Canada. W. Lau's co-authors include Donald N. Buell, D. Facklam, Patricia M. Flynn, Nita L. Seibel, James J. Keirns, Kieren A. Marr, David W. Denning, Thomas F. Patterson, Voravit Ratanatharathorn and Andrew J. Ullmann and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Alimentary Pharmacology & Therapeutics and Journal of Infection.

In The Last Decade

W. Lau

9 papers receiving 863 citations

Peers

W. Lau

EPIDE

PHARM

PRM

D. Facklam United States

Maria J. G. T. Rüping Germany

Marta Torres-Narbona Spain

Mark Bresnik United States

Fernanda Silveira Brazil

Hubert B. Haywood United States

Susan K. Bradshaw United States

Marisa Zenaide Ribeiro Gomes Brazil

Lorena Noriega Chile

E. Biraghi Italy

D. Facklam United States

W. Lau

767 ×0.9

641 ×0.9

EPIDE

175 ×0.9

139 ×0.9

PHARM

104 ×0.9

PRM

Citations per year, relative to W. Lau W. Lau (= 1×) peers D. Facklam

Countries citing papers authored by W. Lau

Since Specialization

Citations

This map shows the geographic impact of W. Lau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Lau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Lau more than expected).

Fields of papers citing papers by W. Lau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Lau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Lau. The network helps show where W. Lau may publish in the future.

Co-authorship network of co-authors of W. Lau

This figure shows the co-authorship network connecting the top 25 collaborators of W. Lau. A scholar is included among the top collaborators of W. Lau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Lau. W. Lau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Castro‐Díaz, David, Christopher R. Chapple, Zalmaï Hakimi, et al.. (2013). Post hoc responder analyses of subjective and objective outcomes using pooled data from 3 randomised Phase III trials of mirabegron in patients with overactive bladder. Neurourology and Urodynamics. 3 indexed citations

Kontoyiannis, Dimitrios P., V. Ratanatharathorn, Jo‐Anne H. Young, et al.. (2008). Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transplant Infectious Disease. 11(1). 89–93. 75 indexed citations

Denning, David W., Kieren A. Marr, W. Lau, et al.. (2006). Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. Journal of Infection. 53(5). 337–349. 209 indexed citations

Ostrosky‐Zeichner, Luis, D. P. Kontoyiannis, John Raffalli, et al.. (2006). International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. European Journal of Clinical Microbiology & Infectious Diseases. 25(1). 69–69. 6 indexed citations

Hiemenz, J., Pablo J. Cagnoni, David Simpson, et al.. (2005). Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant. Antimicrobial Agents and Chemotherapy. 49(4). 1331–1336. 122 indexed citations

Seibel, Nita L., Cindy L. Schwartz, Antonio Arrieta, et al.. (2005). Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients. Antimicrobial Agents and Chemotherapy. 49(8). 3317–3324. 176 indexed citations

Ostrosky‐Zeichner, Luis, D. P. Kontoyiannis, John Raffalli, et al.. (2005). International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. European Journal of Clinical Microbiology & Infectious Diseases. 24(10). 654–661. 145 indexed citations

Bester, A J, et al.. (2005). A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Alimentary Pharmacology & Therapeutics. 21(7). 899–907. 97 indexed citations

Lau, W., et al.. (2004). Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Alimentary Pharmacology & Therapeutics. 20(4). 475–481. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact